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doi:10.1016/j.jtcvs.2004.04.016552 The Journal of Thoracic and CardioObjective: We studied the pathologic features, cellular phenotypes, and matrix
remodeling of clinical pulmonary-to-aortic valve transplants functioning up to 6
years.
Methods: Nine autografts and associated vascular walls early (2-10 weeks) and
late (3-6 years) postoperatively were examined by using routine morphologic
methods and immunohistochemistry. In 4 cases autograft and homograft cusps
were obtained from the same patients.
Results: Autografts had near-normal trilaminar cuspal structure and collagen archi-
tecture and viable valvular interstitial and endothelial cells throughout the time
course. In contrast, cusps of homografts used to replace the pulmonary valves in the
same patients were devitalized. In early autograft explants, 19.3% 2.4% of cuspal
interstitial cells were myofibroblasts expressing -actin. In contrast, myofibroblasts
comprised only 6.0%  1.1% of cells in late explants and 2.5%  0.4% and 4.6%
 0.8% of cells in normal pulmonary and aortic valves, respectively (P  .05). In
early autografts only 12.0%  4.6% of endothelial cells expressed the systemic
arterial endothelial cell marker EphrinB2, whereas later explants had 85.6% 5.4%
of endothelial cells expressing EphrinB2 (P  .05). In early autografts 43.8% 
8.8% of interstitial cells expressed metalloproteinase 13, whereas late autografts had
11.4% 2.7% of interstitial cells expressing matrix metalloproteinase 13 (P .05).
Collagen content in autografts was comparable with that of normal valves and was
higher than that seen in homograft valves (P .005). However, autograft walls were
damaged, with granulation tissue (early) and scarring, with focal loss of normal
smooth muscle cells, elastin, and collagen (late).
Conclusions: The structure of pulmonary valves transplanted to the systemic circu-
lation evolved toward that of normal aortic valves. Key processes in this remodeling
included onset of a systemic endothelial cell phenotype and reversible plasticity of
fibroblast-like valvular interstitial cells to myofibroblasts.
Replacement of a diseased aortic valve by means of transplantationof the patient’s own pulmonary valve into the aortic position, firstdescribed by Donald N. Ross in 1967,1 has shown superior hemo-dynamic results in both pediatric and young adult patients.2-4However, the pathologic features of pulmonary autograft valves(PAVs) have not been systematically described.
We documented the evolution of the morphologic features of clinical pulmonary
autografts functioning up to 6 years, compared pulmonary autografts and cryopre-
served homografts implanted in the same patients and removed simultaneously, and
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lular matrix (ECM) of PAV.
Methods
We studied 9 PAV cusps and 8 associated vascular walls collected
from 4 centers after 2 to 10 weeks (early, n  3) and 3 to 6 years
(late, n  6), at reoperation (n  4), transplantation (n  3) or
autopsy (n  2) from patients 3 to 49 years (mean, 25.9  18
years) of age (Table 1). Cryopreserved homograft valves used for
replacement of the pulmonary valves were obtained from 4 of the
same patients (early, n  3; late, n  1). Nondiseased pulmonary
valves (n 5) and aortic valves (n 5) obtained at autopsy served
as control tissue. All valves were obtained according to a discarded
tissue protocol approved by the Human Research Committee at
Brigham and Women’s Hospital.
Histologic Characterization: General Morphology and
ECM
Specimens were fixed in 10% buffered formalin, and those not
obtained at Brigham and Women’s Hospital, Boston, Mass, were
shipped as necessary. PAVs were dissected in the middle portion
of the cusps through the adjacent wall, conventionally processed,
and embedded in paraffin. Paraffin blocks were then stored until
use. Sections were cut at 6 m and stained with hematoxylin and
eosin for general morphology; Movat pentachrome stain for col-
lagen, elastin, and proteoglycans; and picrosirius red viewed under
polarized light for collagen architecture.5,6 Immunohistochemical
and morphometric studies are described below.
Characterization of Cell Phenotypes and Expression of
Proteolytic Enzymes
Markers of cell phenotypes and expression of proteolytic enzymes
were identified by means of immunohistochemistry. Myofibro-
blasts were defined as cells showing antibody reaction to both
-smooth muscle actin (-SMA; microfilaments, Dako) and vi-
mentin (intermediate filaments, Dako).7 Cells expressing vimentin
only were classified as fibroblasts. Inflammatory cells were iden-
tified with antibodies to CD68 (macrophages, Dako) and CD45 (T
cells, Dako). Mouse monoclonal antibody against the human ma-
trix metalloproteinase 13 (MMP-13/collagenase 3, Calbiochem)
was used to determine expression of proteolytic enzymes.
MMP-13 staining was performed using antigen-unmasking pre-
treatment with commercially available proteinase K solution for 5
minutes at room temperature. Phenotypic changes of valvular
endothelium were identified by antibodies to CD31 (Dako) and
EphrinB2 (specific for arterial endothelial cells; preparation details
below).8 Immunohistochemistry was done by using the avidin-
biotin-peroxidase method. Macrophages (CD68 cells) in the
valve cusps were used as an internal positive control for MMP-13
staining.9 Adjacent pulmonary artery and aortic wall served as
internal control tissues for the EphrinB2 stain. Adjacent sections
treated with nonimmune IgG served as negative controls.
Development and Characterization of the Monoclonal
Antibody for EphrinB2
EphrinB2 is a marker of systemic arterial endothelium.8 Armenian
hamsters were injected 3 times with 10 g of the extracellular
The Journal of Thoracidomain of mEphrinB2 fused to Fc at weekly intervals. Serum was
tested for EphrinB2 reactivity 2 weeks after the third injection. A
booster injection (10 g) was given, and 3 days thereafter, ham-
sters were killed. Splenocytes were fused with SP2/0 murine
myeloma cells. Two weeks after fusion, hybridoma supernatants
were tested in ELISA assays. After limited dilution, one stable
clone (5G9) was obtained. This clone was tested further by means
of FACS analysis, immunoblotting, and immunohistochemistry.
Cell and Collagen Quantitation and Statistical
Analysis
Valve thickness was measured with a linear eyepiece reticle (10
mm, 0.1 mm divisions; Fisher Scientific). Cell density was mea-
sured as the mean number of cells per 10 high-power fields (400)
and expressed as cell numbers per square millimeter of the tissue
section. The -SMA– and MMP-13–positive fraction was aver-
aged over 5 representative high-power fields (400). The ratio of
EphrinB2 cells to total CD31-expressing cells was calculated for
each cusp. Valvular collagen content was measured by means of a
previously established technique.5 In brief, a color threshold was
defined by using the negative background (black) for each sample.
The collagen content was calculated by means of subtraction of the
negative area from the total area of the valve. Statistical analysis
used 1-way analysis of variance, followed by the Fisher test. Data
were presented as means  SEM.
Results
Morphology of Pulmonary Autograft Valves
The morphologic features of early and late PAVs, normal
pulmonary and aortic valves, and, where available, ho-
mograft valves are summarized in Figures 1 to 3.
Valve cusps. Analogous to aortic (Figure 1, A, panels g
and h),10 normal pulmonary valves had 3 well-defined tissue
layers (Figure 1, A, panels a and b), each containing cells
and characteristic ECM composition and configuration: (1)
the fibrosa, rich in collagen; (2) the centrally located spon-
giosa, with loosely arranged collagen and proteoglycans;
and (3) the ventricularis, enriched in elastic fibers. Both
early and late PAV cusps (Figure 1, A, panels c-f) showed
near-normal 3-layered structure and intact elastin; well-
preserved collagen microstructure detected with picrosirius
red; usual outflow surface corrugations; minimal inflamma-
tory cells, including macrophages (CD68) and T lympho-
cytes (CD45); and absence of calcification or thrombi.
Intimal thickening (pannus formation) was present on the
ventricular aspect of some cusps, extending variably from
the proximal to the distal portion of the valve. Because of
pannus and increased underlying cuspal thickness, PAVs
were approximately 3 times thicker than normal pulmonary
valves and similar in thickness to aortic valves (1.4  0.3
mm for early, 0.9  0.2 mm for late, 0.3  0.1 mm for
normal pulmonary, and 0.7  0.1 mm for normal aortic;
Figure 1, B). Interstitial cell density was higher in both early
and late PAVs than in normal valves (Figure 1, B). In
particular, cell numbers were significantly increased in the
2fibrosa (634 98 cells/mm for early PAVs and 670 264
c and Cardiovascular Surgery ● Volume 128, Number 4 553
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cells/mm2 for early PAVs and 732 243 cells/mm2 for late
PAVs) but not spongiosa of PAVs relative to normal pul-
monary valves had 378  147 cells/mm2 in the fibrosa and
381  182 cells/mm2 in the ventricularis (P  .05).
Quantitative analysis of collagen demonstrated preserved
collagen structure in PAV cusps (62.7%  5.7% for early
PAVs and 62.8%  6.7% for late PAVs) that was compa-
rable with that of normal valves (60.5%  9.5% for pul-
monary valves and 68.3%  0.7% for aortic valves) and
decreased collagen in homograft valve cusps (33.3% 
7.7%, P  .005) obtained from the same patients (Figure 1,
C).
Aortic walls. PAV walls showed variable granulation
tissue in early explants and loss of medial smooth muscle
cells and elastin (Figure 2, A). They had lower collagen
birefringence detected with picrosirius red under polarized
light compared with that seen in normal valve walls (Figure
2, B). Late PAVs had variable disruption of structure, scar-
ring, or both, without inflammation or calcification.
Comparison of pulmonary-to-aortic autografts and pul-
monary homografts in the same patient. In contrast to the
preserved architecture of PAVs, homograft valves from the
pulmonary site implanted and removed simultaneously from
4 patients showed the following: (1) loss of interlayer de-
marcations; (2) flattening of outflow surface corrugations;
(3) structural deterioration of ECM, with collagen hyalin-
ization and loss of normal structural layers and cellularity;
and (4) minimal tissue overgrowth (Figure 1, A, panels i-j).
These findings on valve homografts confirm and the data
11
TABLE 1. Clinical data
Age/sex Duration Indication for PAV
Early
38/M 2 wk Calcific stenosis of CBAV
7/F 8 wk Tunnel-type subaortic stenosis, CBAV
13/M 10 wk CBAV stenosis
Late
3/M 2.5 y Calcific AV stenosis
38/M 3.3 y Calcific stenosis of CBAV
48/M 5 y Calcification of CBAV
13/F 5.5 y Complex congenital heart disease
24/M 6 y Calcification of CBAV
49/M 6 y CBAV
PAV, Pulmonary autograft valve; CBAV, congenital bicuspid aortic valve; A
aortic valve regurgitation; PH, pulmonary homograft.
*Brigham and Women’s Hospital, Boston, Mass.
†University of Colorado Health Sciences Center, Denver, Colo.
‡Cardiac, Thoracic and Vascular Surgery, Inc, St Louis, Mo.
§Children’s Hospital, Boston, Mass.below extend those previously reported by our laboratory.
554 The Journal of Thoracic and Cardiovascular Surgery ● OctoPAVs and homografts obtained from the same patients
are compared in Figure 3. Cell density of early PAVs was
greater than that of normal valves but decreased to near-
normal levels in late PAVs (625  44 cells/mm2 for early
PAVs and 474  36 cells/mm2 for late PAVs vs 351  58
cells/mm2 for normal pulmonary valves and 310  59
cells/mm2 for normal aortic valves, P  .05). In contrast,
homografts showed progressive loss of cells (245, 336, 90,
and 29 cells/mm2 at 2, 8, and 10 weeks and 3 years,
respectively).
Phenotypic Changes and Proteolytic Enzyme
Expression in Interstitial Cells of Pulmonary
Autograft Valves
We compared the phenotype of interstitial cells in normal
valves and PAV explants (Figure 4). In normal pulmonary
and aortic valves only 2.5%  0.4% and 4.6%  0.8%,
respectively, of cells expressed -SMA; these cells were
localized in the immediate subendothelium in the proximal
(near the annulus) and middle portions (Figure 4, A, a and b,
and Figure 4, B). In contrast, 19.3%  2.4% of interstitial
cells of early PAVs expressed -SMA, indicating modula-
tion of the quiescent fibroblast-like interstitial cells of nor-
mal valves to myofibroblasts (Figure 4, A, d and e, and
Figure 4, B). Cells observed in overgrowing pannus ex-
pressed predominantly -SMA (Figure 4, A, d). Late PAVs
had limited (6.0%  1.1%) subendothelial distribution of
-SMA cells, which was similar to that seen in normal
valves (Figure 4, A, g, h, and Figure 4, B).
Furthermore, 43.8%  0.8% of interstitial cells in early
Explantation circumstances Source
Tissue
examined
cardial infarction Autopsy* A, H, W
ventricular failure Transplant† A, H, W
ythmia Autopsy† A, H, W
, pulmonary hypertension, PH
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Transplant† A, W
ntricular hypertrophy, aortic
ilation
Transplant* A, H, W
tic dilation with AVR Reoperation‡ A, W
tic dilation with AVR, calcified PH Reoperation§ A
tic dilation with AVR Reoperation‡ A, W
tic dilation with AVR Reoperation‡ A, W
ograft cusp; H, homograft cusp; W, autograft wall; AV, aortic valve; AVR,Myo
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, autPAVs expressed matrix remodeling enzymes (Figure 5). In
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CDFigure 1. Morphologic features and collagenous architecture of PAVs. A, Three distinct layers are present in
normal pulmonary valve (PV; a-b): the fibrosa (f), with an abundance of collagen (yellow); the spongiosa (s), with
glycosaminoglycans (blue-green); and the ventricularis (v), with elastin (black). Both early and late pulmonary
autografts (PAV; c-f) showed near-normal 3-layered structure and intact elastin, usual outflow surface corruga-
tions, and well-preserved collagen microstructure detected with picrosirius red. This was similar to that seen in
normal aortic valves (AV; g-h). Homograft valves (i-j) showed loss of interlayer demarcations, flattening of the
normal outflow surface corrugations, and structural deterioration of the ECM revealed with picrosirius red staining
under polarized light, which demonstrated that collagen fibers were almost undetectable and had lower birefrin-
gence than those in normal valves. (Original magnification of all panels 100.) *Pannus formation. B, Valve
thickness and interstitial cell density in PAVs compared with those in normal aortic valves (AV) and pulmonary
valves (PV). *Significant differences between all combinations of pulmonary valves and early PAVs versus late
PAVs and aortic valves (P < .05); †significant differences in cell density between all sets of valves (P < .05); no
difference was found between pulmonary valves and aortic valves. C, Collagen accumulation in PAVs compared
with that in normal aortic valves (AV), pulmonary valves (PV), and homograft valves (H). *Statistically significant
decrease in collagen content in homograft valves compared with that in PAVs and normal valves.
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explants expressed MMP-13 (P  .005). Normal aortic and
pulmonary valves expressed miniscule amounts of MMP-13
(0.7% and 0.3%, respectively).
Homografts had no detectable immunoreaction to vimen-
tin, -SMA, or MMP-13.
Figure 2. Arterial wall of pulmonary autografts. A, Movat penta-
chrome stain shows overall morphologic features of a normal
pulmonary valve compared with that of a PAV and associated
arterial wall (top). (Original magnification 40.) The middle panel
demonstrates loss of elastin (black) and accumulation of colla-
gen (yellow), suggesting scarring formation in late PAVs. (Origi-
nal magnification 400.) Immunohistochemistry for -SMA
shows loss of medial smooth muscle cells (bottom) in late PAVs.
(Original magnification 400; bar  50 m.) B, Late PAV walls
showed lower collagen birefringence compared with that seen in
normal valve wall (arrows). (Original magnification 40.)556 The Journal of Thoracic and Cardiovascular Surgery ● OctoPhenotypic Changes of Endothelial Cells of Pulmonary
Autograft Valves
As seen in Figure 6, and similar to results seen in normal
valves, early and late PAVs were covered by a layer of
CD31 endothelial cells. To elucidate the phenotypic dif-
ferences between aortic and pulmonary valve endothelium,
we stained aortic and pulmonary valves with an antibody for
EphrinB2 (a marker of arterial endothelium8). EphrinB2
was detected nearly uniformly (98.8%  3.2%) in endothe-
lial cells of normal aortic but not pulmonary valves (Figure
6). PAVs were stained with EphrinB2 antibody to determine
whether transplantation of pulmonary valves to the aortic
position (with higher transvalvular pressure gradient, flow,
and oxygen tension) could modulate the phenotype of en-
dothelial cells. Valvular endothelial cells of early PAV
explants had only patchy expression of EphrinB2 on both
inflow and outflow surfaces (12.0%  4.6%). However, an
increased population of endothelial cells expressed the
CD31/EphrinB2 phenotype (85.6%  5.4%) in late
PAVs (Figure 6). In contrast, homografts from the same
 
Figure 3. Comparative morphologic features of autografts and
homografts obtained from the same patients. Autograft valves had
near-normal structure and cellular population (a, c, and e). In
contrast, homografts from the same patients (b, d, and f) had
progressive collagen hyalinization and loss of cellularity. (Orig-
inal magnification 400; bar  50 m.)patients had neither CD31 nor EphrinB2 cells.
ber 2004
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A fundamental problem inherent in the use of other existing
biologic valve substitutes is their lack of viability and con-
sequent failure to remodel ECM, repair structural injury,
and potentially adapt to the somatic growth of pediatric
recipients.12 This study shows that in contrast to other
contemporary biologic valve substitutes and similar to nat-
ural valves, PAV transplants uniquely preserve interstitial
and endothelial cell viability, remodel ECM, adapt to new
environmental demands, and potentially grow. PAVs main-
tained functional collagen architecture and cell viability
after 3 to 6 years. There was minimal inflammation and no
calcific deposits or thrombi. Interstitial cells in these PAVs
were initially activated and later normalized both interstitial
and endothelial cell phenotypes toward those of normal
aortic valves. PAV cusps were as thick as aortic cusps, in
part because of increased intimal thickening and deep cel-
lularity, possibly as a result of cell proliferation or progen-
itor cell recruitment.
Comparison of Autograft and Homograft Valves
In contrast to the preserved cells and ECM of PAVs, ho-
mografts had progressive loss of cells and structural dete-
rioration. As we previously described,11 progressive loss of
interstitial cells associated with a lack of active metabolic
functions and ECM production in homografts suggests that
their durability depends critically on the quality of their
original collagen. Moreover, the largely normal structure
and cellular population of PAVs were similar to those of
aortic valves from orthotopic heart transplants.11 In contrast
to isolated homograft valve replacements, valves from
transplanted hearts suffer less ischemic time and no cryo-
preservation.
Adaptive Remodeling of Clinical Pulmonary Autograft
Valves
Heart valves have a layered architecture and highly special-
ized, functionally adapted ECM,10,13 which collectively ac-
commodate repetitive changes in shape and dimension
throughout the cardiac cycle. In normal valves interstitial
valvular cells synthesize ECM and mediate its ongoing
repair and remodeling. In existing biologic valve substi-
tutes, cells are nonviable, adaptive remodeling of ECM
cannot occur, and repair of structural injury is impossible.
This often results in impaired durability caused by calcifi-
cation and collagen deterioration.12,13
The major cell population of normal cardiac valves is
comprised of fibroblast-like interstitial cells. Recently, it has
been demonstrated that mechanical forces14 or injury15 can
induce phenotypic changes in valvular cells. The present
study demonstrates transient activation of valvular intersti-
tial cells to myofibroblasts in vivo in response to environ-
mental change. Nevertheless, the mechanisms inducing and
regulating the interstitial cell response to physical signals
The Journal of ThoraciFigure 4. Immunophenotypes of interstitial cells of normal pulmo-
nary valves and autograft explants. A, In normal pulmonary valves
(PV) fibroblast-like interstitial cells expressed predominantly vimen-
tin but not -SMA (a-c). Cells that stained positive for -SMA were
localized immediately below the endothelium. *Pannus formation in
early PAVs (d). In early PAVs a large population of cells in the
spongiosa and the ventricularis expressed both vimentin and
-SMA, suggesting modulation to myofibroblasts in early PAVs (d-f).
In late PAVs the subendothelial distribution of -SMA/vimentin-
positive myofibroblasts among the interstitial cells resembled the
quiescent fibroblast-like cell population of the normal valves (g-i).
(original magnification: a, d, and g, 100; b, c, e, f, h, and i, 400.) B,
An initial increase in the number of -SMA cells in early PAVs
eventually normalized to aortic valve (AV) levels in late PAVs.
*Difference between early PAVs and all other valve combinations (P
< .01). PV, Pulmonary valve.c and Cardiovascular Surgery ● Volume 128, Number 4 557
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phenotypic modulation of interstitial cells as a response to
injury in clinical mitral valves with myxomatous degener-
ation6 and experimental tissue-engineered heart valves.16
Interestingly, the persistence of the myofibroblast pheno-
type in myxomatous valves removed at surgical intervention
suggests that, in contrast to PAVs, mechanical equilibrium
is not ultimately achieved.6 The signaling pathways and
gene expression patterns characteristic of responses to vas-
cular endothelial and vascular smooth muscle cells to me-
chanical stress might be operative in both valvular endothe-
lial and interstitial cells.17
Interstitial collagenases mediate the initial step of colla-
Figure 5. Proteolytic enzyme expression in pulmonar
Interstitial cells in the early PAVs expressed higher lev
superficial cells showed weak expression of MMP-13
(Original magnification 400; bar 50 m.) PV, Pulmon
cells expressing MMP-13 in early PAVs decreases to
PAVs. *Significant difference in MMP-13 expression
normal valves.gen degradation through breakdown of the native helix of
558 The Journal of Thoracic and Cardiovascular Surgery ● Octothe fibrillar collagen network (type I is most abundant,
comprising approximately 70% of the total collagen in
valves).10,18 MMPs, particularly MMP-13, are also involved
in ECM breakdown in normal tissues and in pathologic
cardiovascular conditions, such as atherosclerosis,9 aortic
aneurysms,19 and myxomatous valve degeneration.6 Early
PAVs had increased expression of MMP-13 by interstitial
cells, probably as an early cell activation response to sur-
gical trauma and subsequent collagen remodeling. How-
ever, late PAVs had lesser expression of MMP-13 compa-
rable with that seen in normal valves. Collagen
birefringence detected with picrosirius red under polarized
light was stronger in both groups of PAVs compared with
ografts compared with that seen in normal valves. A,
f MMP-13 than normal valves. In late PAVs only a few
gesting cuspal intimal proliferative lesion formation.
alve. B, An initial increase in the number of interstitial
ic valve (AV) and pulmonary valve (PV) levels in late
rly PAVs compared with that seen in late PAVs andy aut
els o
, sug
ary v
aort
in eathat seen in homograft valve cusps.
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EphrinB2 identifies a stable genetic difference between ar-
terial and venous endothelial cells.8 We demonstrated that
endothelial cells from normal human aortic but not pulmo-
nary valves express EphrinB2. Moreover, early PAV cusps
showed only sporadic expression of EphrinB2, although late
PAV explants had strong EphrinB2 expression.
Our data provide the first demonstration in vivo in hu-
man subjects that endothelial cells covering valves of left-
sided but not right-sided heart valves express EphrinB2 and
suggest that this expression can be induced by alterations in
the local valvular environment. It is probable that this
change in valvular endothelial cell phenotype in the PAV
was due to altered mechanical stress, oxygen tension, or
both, which is different in the systemic compared with the
pulmonary circulation. However, it is uncertain that the
endothelial cells present on the cusps of the explant were
derived from those present initially because repopulation of
transplanted valve tissue by circulating endothelial progen-
itor cells20 or cell migration across the anastomosis from the
Figure 6. Immunophenotype of endothelial cells of norma
normal aortic valve (AV) but not pulmonary valve (PV) e
patchy expression of EphrinB2 (arrow, middle panels), w
the CD31/EphrinB2 phenotype in late PAVs (bottom).
EphrinB2 expression in PAVs toward levels of a norm
PAVs and aortic valves versus pulmonary valves (PVsadjacent preexisting aortic wall cannot be excluded.
The Journal of ThoraciClinical Implications
This work describes changes in cells and ECM that accom-
pany the evolution of the PAV from a structure character-
istic of the pulmonary valve to one resembling the aortic
valve. These changes are likely driven by the combined
effects of biomechanical forces, oxygen tension, and peri-
operative trauma. However, irrespective of the mechanisms
involved, the presence of functionally intact interstitial cells
in PAV cusps suggests that these valve substitutes are
capable of ongoing repair of the valvular collagen and other
ECMs, adaptation, and potentially growth by means of cell
proliferation and matrix synthesis. These features are not
exhibited by glutaraldehyde-pretreated bioprostheses, cryo-
preserved homograft valves, or other contemporary tissue
valve substitutes.
In contrast to the high quality of the PAV cuspal tissue,
the pulmonary autograft walls examined in the present study
were not well preserved and showed extensive structural
disruption. One potential cause of these changes is the
disruption of the vasa vasorum by surgical dissection. More-
ves and autograft explants. A, EphrinB2 was detected in
elium (top panels). Endothelial cells of early PAVs had
s an increased population of endothelial cells expressed
inal magnification 400.) B, Progressive increase of
rtic valve (AV). *Significant differences between late
early PAVs (P < .01).l val
ndoth
herea
(Orig
al aoover, most of the patients in our study had congenitally
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high frequency of histologic abnormalities of the aorta and
pulmonary arterial walls and a susceptibility to dilation of
the aortic root and ascending aorta,21 probably caused by
smooth muscle cell apoptosis,22 and deficient ECM and
matrix remodeling.23 This suggests that an intrinsic struc-
tural abnormality might have contributed to the observed
dilation in the majority of late clinical specimens examined
in this study. We are unaware of associated pulmonary
valvular cuspal histologic abnormalities in patients with
congenitally bicuspid aortic valve. The histologic results in
the 7 patients with and the 2 patients without bicuspid
valves were consistent, and we believe that it was reason-
able to combine the data from cusps obtained from those
patients. Although aneurysmal expansion of the aortic root
of clinical significance occurs only in a minority of PAV
recipients,2,24 experimental and clinical studies suggest that
the aortic roots of PAVs increase in diameter to a greater
extent than would be expected through normal growth25-29
and that passive dilation might play a role. However, the
present study does not permit a distinction between passive
dilation and active growth.
Limitations of This Study
The retrospective analysis of these unusual surgical speci-
mens pooled from several institutions in this study enabled
us to answer important questions regarding the fate of
PAVs. Nevertheless, this study has several limitations.
Treatment of the study specimens was nominally the same,
but we cannot absolutely exclude heterogeneity in specimen
procurement procedures and tissue handling that could be
important. Because of a limited number of specimens and
the lack of truly sequential information on a specific spec-
imen, our findings are only suggestive of mechanisms. The
cause of aortic wall dilation in these patients and the role in
aortic dilation of preexisting abnormalities of the vascula-
ture in the patients with bicuspid valves could not be deter-
mined.
Conclusions
This study shows that PAVs respond to mechanical and
other characteristics of the systemic circulation. Our study
suggests new insight into the mechanisms of ECM remod-
eling in heart valves in general and the adaptation of PAVs
to their new environment. These data show that the inter-
stitial cells of clinical pulmonary autografts are viable and
exhibit considerable plasticity; they respond to altered con-
ditions by means of reversible phenotypic changes and
increased expression of proteolytic enzymes associated with
ECM remodeling. Collectively, this and previous studies are
consistent with a hypothetic general paradigm by which
valves adapt to environmental changes: under mechanical
stresses and other stimuli, the interstitial cells become acti-
560 The Journal of Thoracic and Cardiovascular Surgery ● Octovated and mediate connective tissue remodeling until me-
chanical equilibrium is restored and the cells return to the
quiescent state. Moreover, endothelial cells can also appro-
priately adjust their phenotype to accommodate an altered
environment.
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